Leveraging the Capabilities of Gamma Delta T Cells: Sebastian Wanless, MD, PhD
Sebastian Wanless, MD, PhD, senior clinical director of TC BioPharm, joins CGTL to discuss the company's development of chimeric co-stimulatory receptor T cells, as well as its clinical programs targeting cancers and infectious diseases.
"As far as I'm aware, this is unique. The are no other companies or researchers that we know of who have developed a product where the CAR only has the co-stimulatory domain." —Sebastian Wanless, MD, PhD, senior clinical director of TC BioPharm
The FDA recently granted orphan drug designation to TC BioPharm for its unmodified allogeneic gamma delta T cell (GDT) product TCB-002 (OmnImmune) for the potential treatment of relapsed/refractory acute myeloid leukemia (AML).
The UK-based cell therapy company, which applies chimeric antigen receptor (CAR) T-cell technology to GDT cells in an effort to make the therapeutic more selective, is also moving toward clinical trials for treatments for a range of cancers, as well as infectious diseases.
Joining CGTL to discuss updates on its clinical programs is Sebastian Wanless, MD, PhD, senior clinical director of TC BioPharm.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
